Filter your search
Cancer diagnosis and treatment represents a significant expenditure in developed healthcare systems. Cancer screening is performed through routine tests such as complete blood counts (CBCs), differentials, and protein markers. However, the global oncology diagnostics market is quickly evolving past established markers and companion diagnostics in the United States, Europe and Japan. Targeted cancer therapies are finding significant demand in emerging middle-income countries such as China and new technologies such as liquid biopsies, next-generation sequencing (NGS) and novel hybridization assays are being developed for cancer detection and diagnosis. Kalorama Information market research covers cancer diagnostics from multiple angles of diagnostic technology and regional demand.
- This Kalorama Information report – The World Market for Cancer Therapeutics and Biotherapeutics (Chemotherapy Agents, Interleukins/interferons, Monoclonal Antibodies, Hormone and Other Therapies) represents the fourth time that Kalorama Information has taken a comprehensive look at oncology therapeutics. The report focuses on several segments for cancer treatment including: Chemotherapy, – Subcategories include Alkylating Agents, Antimetabolites, Cytotoxic […]January 1, 2012$1,500 – $2,500This bundle provides customers with three of the most intensely researched Kalorama Information reports covering the diagnostic industry authored by Shara Rosen, R.T., M.B.A. in 2010 and 2011 These reports will be provided in one PDF, each with its own table of contents. The bundle allows customers to save almost $4,500 off the cost of […]March 1, 2011NOTE: This report is based on 2008 Market Data The current population of India is 1.14 billion, and with a growth rate of 1.7%, India will surpass China to become the world’s largest country around 2030. For diagnostic manufacturers, this enormous market is just now being recognized as a high-growth area as the pace of […]June 1, 2010$4,200 – $8,400Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And […]April 1, 2010As Kalorama Information’s lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality have arrived. But is healthcare ready? Kalorama believes that the drive for wellness and the attention surrounding healthcare reform will focus attention on rapid diagnostics. However, according to Shara Rosen, […]November 1, 2009$250 – $3,395It is commonly asserted that in vitro diagnostics is a recession-proof industry. Kalorama Information’s lead diagnostic analyst Shara Rosen tests that assumption and provides strategic conclusions in Shara Rosen’s new report In Vitro Diagnostics in a Recessionary Economy. The economic problems that began slowing the U.S. economy keep spreading, with Europe and Japan following America […]May 1, 2009$2,500 – $5,000Dominated by Lab Corp and Quest, the clinical laboratory services market is growing as new competitors enter. An essential part of the health industry, it is estimated that approximately 80% of physician’s diagnoses are a result of laboratory tests. In addition to diagnosing patients, clinical lab testing is performed to evaluate disease progression, monitor drug […]November 1, 2008This Kalorama Information report, Companion Diagnostics Markets (A Realistic Assessment of the Opportunities, Challenges, Key Players and Important Trends in Personalized Medicine) is truly a real-world guide to the potential market for companion diagnostics. Essentially the co-development of testing products to enhance the value and efficacy of a therapeutic, companion diagnostics is widely seen as […]June 1, 2008Who are the major players in testing for the number two killer in the world? What revenues can companies competing in this market expect in the next five years? How will the impact of trends such as an increased role of pharmacodiagnostics, the use of multiplex assays and a new emphasis on service products influence […]March 1, 2008The current population of India is 1.065 billion, and with a growth rate of 1.7%, India will surpass China to become the world’s largest country around 2030. For diagnostic manufacturers, this enormous market is just now being recognized as a high-growth area as the pace of economic growth in India accelerates and modern laboratory practices […]December 1, 2006